Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Staffer Dorsey Returns To FDA As Sharfstein’s Senior Counselor

This article was originally published in The Tan Sheet

Executive Summary

David Dorsey, a top staffer on the Senate Health, Education, Labor and Pensions Committee and previously a dietary supplement and tobacco issues advisor at FDA, will return to the agency as a senior counselor for Acting Commissioner Josh Sharfstein

You may also be interested in...



FDA Chief Counsel Has History With Sharfstein

FDA named Ralph Tyler, currently Maryland's insurance commissioner, as the agency's new chief counsel

FDA Chief Counsel Has History With Sharfstein

FDA named Ralph Tyler, currently Maryland's insurance commissioner, as the agency's new chief counsel

FDA Chief Counsel Has History With Sharfstein

FDA named Ralph Tyler, currently Maryland's insurance commissioner, as the agency's new chief counsel

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel